Your browser doesn't support javascript.
loading
Computational design of experimentally validated multi-epitopes vaccine against hepatitis E virus: An immunological approach.
Anwar, Tasneem; Ismail, Saba; Parvaiz, Fahed; Abbasi, Sumra Wajid; A Al-Abbasi, Fahad; M Alghamdi, Amira; Al-Regaiey, Khalid; Ul-Haq, Asad; Kaleem, Imdad; Bashir, Shahid; Waheed, Yasir.
Afiliación
  • Anwar T; Department of Biosciences, COMSATS University Islamabad (CUI), Islamabad, Pakistan.
  • Ismail S; Department of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
  • Parvaiz F; Department of Biosciences, COMSATS University Islamabad (CUI), Islamabad, Pakistan.
  • Abbasi SW; Department of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
  • A Al-Abbasi F; Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
  • M Alghamdi A; Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Al-Regaiey K; Department of Physiology, King Saud University, Riyadh, Saudi Arabia.
  • Ul-Haq A; Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea.
  • Kaleem I; Department of Biosciences, COMSATS University Islamabad (CUI), Islamabad, Pakistan.
  • Bashir S; Neuroscience Center, King Fahad Specialist Hospital Dammam, Dammam, Saudi Arabia.
  • Waheed Y; Office of Research, Innovation & Commercialization, Shaheed Zulfiqar Ali Bhutto Medical University (SZABMU), Islamabad, Pakistan.
PLoS One ; 18(12): e0294663, 2023.
Article en En | MEDLINE | ID: mdl-38096182
ABSTRACT
Hepatitis E virus (HEV) is one of the leading acute liver infections triggered by viral hepatitis. Patients infected with HEV usually recover and the annual death rate is negligible. Currently, there is no HEV licensed vaccine available globally. This study was carried out to design a multi-epitope HEV peptide-based vaccine by retrieving already experimentally validated epitopes from ViPR database leading to epitope prioritization. Epitopes selected as potential vaccine candidates were non-allergen, immunogenic, soluble, non-toxic and IFN gamma positive. The epitopes were linked together by AAY linkers and the linker EAAAK was used to join adjuvant with epitopes. Toll-like receptor (TLR)-4 agonist was used as an adjuvant to boost efficacy of the vaccine. Furthermore, codon optimization followed by disulfide engineering was performed to analyse the designed vaccine's structural stability. Computational modeling of the immune simulation was done to examine the immune response against the vaccine. The designed vaccine construct was docked with TLR-3 receptor for their interactions and then subjected to molecular dynamic simulations. The vaccine model was examined computationally towards the capability of inducing immune responses which showed the induction of both humoral and cell mediated immunity. Taken together, our study suggests an In-silico designed HEV based multi-epitope peptide-based vaccine (MEPV) that needs to be examined in the wet lab-based data that can help to develop a potential vaccine against HEV.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Virus de la Hepatitis E Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Virus de la Hepatitis E Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2023 Tipo del documento: Article